



alzchem
group

AGILE SCIENCE PURE RESULTS

alzchem
group



Q2

2022

ANDREAS NIEDERMAIER, CEO
DR. GEORG WEICHSELBAUMER, CSO

July 26, 2022

DISCLAIMER

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This presentation contains forward-looking statements about the business, financial condition and earnings performance of the Alzchem Group. These statements are based on assumptions and projections resting upon currently available information and present estimates. They are subject to a multitude of uncertainties and risks. Actual business development may therefore differ materially from what has been expected. Beyond disclosure requirements stipulated by law, Alzchem does not undertake any obligation to update forward-looking statements.

Unless stipulated otherwise, all values are rounded up or down in accordance with the commercial rounding practices. Please note that differences can result from the use of rounded amounts and percentages.

AGENDA – ANALYST PRESENTATION Q2 2022

- I. **Executive Summary**
- II. Business and financial details
- III. Back-Up

HIGHLIGHTS

Successful first half-year despite challenging environment



Sales at record levels due to successful adjustment of contract prices



EBITDA matches previous year despite high energy and raw material costs



Russia-Ukraine war intensifies shortages and price increases on raw material, energy and logistics markets



Strong demand in human nutrition, steel and pharma as well as automotive industry



Supply chain requires increase in net working capital; short term financing required



Creapure® capacity expansion is on schedule with expected completion in Fall 2022

FINANCIAL OVERVIEW

Sales growth of 25% largely via price adjustments



Alzchem Group

	Q2 2021	Q2 2022	yoy %	2021 1 - 6	2022 1 - 6	yoy %
SALES (in M€)	111.0	140.4	+26.5%	215.3	269.8	+25.3%
EBITDA (in M€)	19.0	17.8	-6.3%	35.7	34.9	-2.3%
EBITDA margin (in %)	17.1%	12.7%	-4.4pp	16.6%	12.9%	-3.7pp
Earnings per Share (in €)	0.90	0.95	+5.6%	1.68	1.71	+1.8%

- High sales in agriculture (Dormex®), in the steel market as well as in the pharmaceutical industry (DCD) support the result
- Cost pass-through possible so far but no impact of price increases on margin; price increases of app. € 54 m. could be achieved
- The war in Ukraine and Covid-19 continue to have a negative impact on business activities
- Despite high market turbulence EBITDA close to previous year in absolute terms
- Earnings per share comparable to the very successful level of the previous year


	DELTA Q2	DELTA 01 - 06
Volume	-7.7%	-1.7%
Price	31.1%	24.9%
Currency	3.1%	2.1%

TURBULENT MARKET ENVIRONMENT – CURRENT DEVELOPMENT

Logistic, raw material und energy costs




Power front year




Crude oil (Brent)



Met-Coke



Natural gas



NATURAL GAS DEPENDENCE

Direct dependence on natural gas is very low, but...



DIRECT



Low direct consumption



Transfer to third parties

INDIRECT



Natural gas-dependent raw materials have seen massive price increases (ammonia, urea,)



Gas fired power plants define power price via merit order mechanism



Competitiveness outside Europe

AGENDA – ANALYST PRESENTATION Q2 2022

- I. Executive Summary
- II. Business and financial details**
- III. Back-Up



NITRALZ®

Perlka®
CALCIUM CYANAMIDE

CaD

BASICS & INTERMEDIATES

The "Basics & Intermediates" segment comprises the production of basic and intermediate products that are marketed as independent products for example in agriculture, steel production and the automotive sector and as raw materials for the manufacture of specialty chemicals.


alzchem
group 

BASICS & INTERMEDIATES SEGMENT (in M€)


Sales significantly above prior year




SALES




EBITDA



SALES



EBITDA



SALES ANALYSIS

	DELTA Q2	DELTA 01 - 06
Volume	- 18.5%	- 4.3%
Price	+ 45.7%	+ 37.3%
Currency	+ 1.0%	+ 0.7%

COMMENTS

- Q2/2022 sales significantly above previous year (~28 %)
- Sales within the metallurgic and pharmaceutical sector significantly above Q2/2021
- The pharmaceuticals, agrochemicals and basic chemicals businesses (NITRALZ®) and agricultural fertilizers (Perlka®) impacted by high cost pressure
- Price adjustments in progress to cover the exorbitant raw material and electricity prices
- EBITDA margin of 1.5 % in Q2/2022 (previous year 8.5 %)



CREAMINO

Dormex[®]

Bioselect[®]

DYHARD[®]

Creapure[®]

SPECIALTY CHEMICALS


The "Specialty Chemicals" segment produces and sells high-quality growth products in the area of specialty chemicals.

SPECIALTY CHEMICALS SEGMENT (in M€)


Encouraging business performance




SALES



EBITDA



SALES



EBITDA



SALES ANALYSIS

	DELTA Q2	DELTA 01 - 06
Volume	+ 0.3%	+ 0.4%
Price	+ 23.2%	+ 18.2%
Currency	+ 5.0%	+ 3.3%

COMMENTS

- Sales in Q2/2022 about 29 % above previous year level
- Demand for building blocks, automotive sector as well as agriculture sector on a persistent high level
- Continued growth in the area of dietary supplements (Creapure® and LIVADUR®)
- Positive volume development of the animal nutrition business (Creamino®)
- Similar to Q1/2022, the ongoing tense raw material and logistic situation was one of the major challenges
- Positive sales development and process optimizations supported the EBITDA, despite the strained economic situation
- Almost stable EBITDA margin of 21.4 % (previous year 24.9 %)



OTHER & HOLDING


The "Other & Holding" segment offers infrastructure and energy supply services at our locations for the chemicals segments and for external customers.

OTHER & HOLDING SEGMENT (in M€)


Development of services in line with 2021




SALES




EBITDA



SALES



EBITDA



SALES ANALYSIS

	DELTA Q2	DELTA 01 - 06
Volume	- 5.7%	- 2.6%
Price	+ 2.7%	+ 2.6%
Currency	± 0.0%	± 0.0%

COMMENTS


- Q2/2022 sales slightly below previous year's level (~3 %)
- Unchanged sales performance compared to previous year (only slight shifts between the services)
- EBITDA in line with sales development, including price adjustments

BALANCE SHEET (in M€)


Increase of balance sheet total and equity ratio



ASSETS



LIABILITIES




- Main impact on asset development from increase in net working capital
- Almost half of the increase in inventories was caused by higher prices, while the other half can be attributed to the necessity for a higher availability due to the economic environment
- Higher sales prices resulted in higher trade receivables
- Deferred tax assets for pension provision decreased following the interest rate increase for pension valuation

- Equity ratio increased from 22.4% to 30.9%; strong increase mainly driven by the reduction of pension provision due to higher interest rates in actuarial assumptions (35.3 M€ net of tax); positive result of 17.4 M€ further increased equity
- Dividend payment of 10.1 M€ in May 2022 reduced equity on the other side
- Current liabilities increased to 50.3 M€ to finance increase in net working capital; regular loan and lease repayments reduced non-current liabilities
- Increase of trade payables of 12 M€ due to higher costs for raw materials and energy;

CASHFLOW (in M€)

Net cashflow impacted by NWC management on both directions



- Net cashflow much lower than comparative; while net result has not changed compared to last year, increase in net working capital leads to much higher cash outflows (inventories about 40 M€ increase)
- Investing cashflow at 15.0 M€ and 1.6 M€ lower than first half year in 2021; some replacement projects have been postponed while we keep on track for our major growth projects (capacity increase Creapure® plant)
- Cash flow for financing activities mirrors development of net working capital; leading to short term financing cash inflows of 50.0 M€
- Regular loan and lease repayments mainly on prior year level; dividend payments of 10.1 M€ reduced financing cashflow

IMPLEMENTING OPERATING TARGETS

Focus on the key growth drivers and sustainability



Implementation of price increases, at least in the amount of the cost increases

SUSTAINABILITY

- Set the path to CO₂ neutral growth and climate neutrality by 2045
- Vision 0 accidents
- Vision 0 waste – promoting circular economy
- Introduction of EU Taxonomy Regulation – Taxonomy compliance
- Organize transition from NFRD (Nonfinancial Reporting Directive) to CSRD (Corporate sustainability Reporting Directive)

Realization and commissioning of Creapure® capacity expansion

Continue to grow NITRALZ® and Creamino® business

Management of COVID-19 effects

MARKETS DEVELOPMENTS


Sales impact / Alzchem's market view as a basis for the outlook



BASICS & INTERMEDIATES




PHARMA EU



METALLURGY




PHARMA RoW



AGRICULTURE
(FERTILIZER)


SPECIALTY CHEMICALS




HUMAN NUTRITION




ANIMAL
NUTRITION



FINE
CHEMICALS



AGRICULTURE




CUSTOM
SYNTHESIS

OUTLOOK 2022 (in M€)


Parity of cost with price increases will determine EBITDA



SALES



EBITDA



COMMENTS

- Adjustment of the upper sales limit (in Q1/2022) from 480 M€ to 520 M€ due to necessary price increases
- Price increases will determine EBITDA – balance short term needs with long-term requirements
- Further growth of the pharmaceuticals, agrochemicals and basic chemicals businesses (NITRALZ®) and the animal nutrition business (Creamino®)
- Stable development in the agricultural, steel and automotive sectors
- On-time commissioning of Creapure® capacities
- Continued high input costs (raw material, power, logistics) and volatility
- USD exchange rate 1.00
- Possible effects of a prolonged war in Ukraine or sudden interruption of gas supplies are not reflected in this forecast and are currently not predictable

FINANCIAL CALENDAR

Upcoming dates



SEP 5 - 6 2022

Fall Conference

SEP 21 2022

Berenberg and Goldman Sachs German Corporate Conference

SEP 22 2022

Baader Investment Conference

OCT 26 2022

Quarterly Statement 3rd Quarter 2022

NOV 15 - 16 2022

Münchner Kapitalmarkt Konferenz

NOV 28 - 30 2022

Deutsches Eigenkapitalforum

**AGILE SCIENCE
PURE RESULTS**

**alzchem
group**



Investor Relations

T +49 8621 86-2888

F +49 8621 86-502888

ir@alzchem.com

AGENDA – ANALYST PRESENTATION Q2 2022

- I. Executive Summary
- II. Business and financial details
- III. Back-Up**

BALANCE SHEET

Alzchem Group




ALZCHEM GROUP (IN T€)	31.12.2021	30.06.2022	Deviation	
Intangible assets	2,329	2,267	-63	-2.7%
Tangible assets	178,806	180,432	1,626	0.9%
Investment properties				
Right of use (assets)	7,686	6,819	-867	-11.3%
Investments accounted for using the equity				
Financials assets	20	20		
Trade receivables				
Other receivables	1,320	1,431	111	8.4%
<i>there of Deferred tax assets for pensions p</i>				
Deferred tax assets	34,924	19,003	-15,921	-45.6%
SUM NON-CURRENT ASSETS	225,086	209,973	-15,113	-6.7%
Inventories	86,676	126,897	40,220	46.4%
Trade receivables	40,841	57,782	16,941	41.5%
Financial assets				
Other receivables	16,454	22,947	6,494	39.5%
Income tax receivables	326	91	-235	-72.2%
Cash and cash equivalents	8,285	10,196	1,912	23.1%
Assets classified as held for sale				
Other assets				
SUM CURRENT ASSETS	152,581	217,913	65,332	42.8%
SUM ASSETS	377,667	427,886	50,218	13.3%

ALZCHEM GROUP (IN T€)	31.12.2021	30.06.2022	Deviation	
Share capital	101,763	101,763		
RETAINED EARNINGS (+) / LOSS (-)	101,127	108,276	7,149	7.1%
Other comprehensive income	-51,104	-15,813	35,291	-69.1%
Own shares	-1,009	-1,009		
SHARE TO THE SHAREHOLDERS	87,630	130,070	42,440	48.4%
Non-controlling interests	1,934	2,020	85	4.4%
SUM EQUITY	89,565	132,090	42,525	47.5%
Provisions for pensions	140,005	91,237	-48,768	-34.8%
Other provisions	24,372	21,308	-3,064	-12.6%
Loans	37,553	32,525	-5,027	-13.4%
Finance lease liabilities	5,793	5,088	-705	-12.2%
Trade liabilities				
Other liabilities	171		-171	-100.0%
Deferred tax liabilities	4,084	4,472	387	9.5%
SUM NON-CURRENT LIABILITIES	211,979	154,630	-57,349	-27.1%
Other provisions	2,968	1,591	-1,377	-46.4%
Loans	10,490	60,750	50,260	479.1%
Finance lease liabilities	1,805	1,737	-68	-3.8%
Finance liabilities				
Trade liabilities	32,780	44,778	11,998	36.6%
Other liabilities	26,220	29,353	3,133	12.0%
Income tax liabilities	1,862	2,958	1,096	58.9%
SUM CURRENT LIABILITIES	76,124	141,166	65,042	85.4%
Sum EQUITY AND LIABILITIES	377,667	427,886	50,218	13.3%

PENSION ACCOUNTING (IFRS)

Alzchem Group (M€)



- Adjustment of market interest rate from 0.5 % → 1.0 %; decreasing impact on provision
- Adjustment of expected pension trend from 1.5 % → 2.0 %; increasing impact on provision
- Adjustment of expected salary trend from 2.5 % → 3.0 %; increasing impact on provision
- Moderately increasing cash payments

INCOME STATEMENT

Alzchem Group



ALZCHEM GROUP (IN T€)	Q1 2021	Q2 2021	Q3 2021	Q4 2021	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Deviation (Q2)	
Revenue	104,321	111,000	95,920	111,052	129,395	140,435			29,435	27%
Increase (+) / Decrease (-) in inventories of finished goods	-2,144	-1,621	6,350	7,442	14,144	14,467			16,088	-992%
Other income	3,983	2,505	2,143	2,729	4,070	5,736			3,231	129%
Raw materials and consumables used	-36,226	-37,538	-42,153	-54,753	-73,537	-74,027			-36,488	97%
Employee benefits expense	-33,038	-35,209	-30,875	-33,045	-34,000	-36,287			-1,078	3%
Other expense	-20,175	-20,143	-17,548	-20,932	-23,003	-32,517			-12,374	61%
EBITDA	16,722	18,993	13,838	12,493	17,070	17,807			-1,186	-6%
Depreciation expense	-5,771	-5,900	-6,206	-6,598	-6,305	-6,299			-399	7%
Impairment										
EBIT	10,951	13,094	7,632	5,895	10,765	11,508			-1,585	-12%
Investment income										
Other interest and similar income	512	244	139	-252	1,181	2,393			2,149	881%
Other interest and similar expense	-425	-413	-431	-434	-603	-643			-230	56%
Financial result	88	-169	-292	-686	578	1,750			1,920	<-1.000
Result from associates										
Result from ordinary business	11,039	12,924	7,340	5,209	11,343	13,258			334	3%
Taxes on income and profit	-3,109	-3,710	-2,608	679	-3,603	-3,629			82	-2%
<i>thereof income tax</i>	-2,737	-3,330	-1,944	-1,036	-2,520	-2,094			1,237	-37%
<i>thereof change from deferred taxes</i>	-373	-380	-663	1,715	-1,082	-1,535			-1,155	304%
Annual result	7,930	9,214	4,733	5,887	7,740	9,630			416	5%
<i>thereof minority interests</i>	43	43	43	43	43	43				
<i>thereof shares held by shareholders</i>	7,887	9,171	4,690	5,844	7,698	9,587			416	5%
Result per share in EUR	0.78 €	0.90 €	0.46 €	0.58 €	0.76 €	0.95 €	- €	- €		

INCOME STATEMENT

Alzchem Group



ALZCHEM GROUP (IN T€)

Revenue
Increase (+) / Decrease (-) in inventories of finished goods and work in progress
Other income
Raw materials and consumables used
Employee benefits expense
Other expense
EBITDA
Depreciation expense
Impairment
EBIT
Investment income
Other interest and similar income
Other interest and similar expense
Financial result
Result from associates
Result from ordinary business
Taxes on income and profit
<i>thereof income tax</i>
<i>thereof change from deferred taxes</i>
Annual result
<i>thereof minority interests</i>
<i>thereof shares held by shareholders</i>
Result per share in EUR

Q2 2021	Q2 2022	Deviation (QoQ)	
111,000	140,435	29,435	26.5%
-1,621	14,467	16,088	-992.4%
2,505	5,736	3,231	129.0%
-37,538	-74,027	-36,488	97.2%
-35,209	-36,287	-1,078	3.1%
-20,143	-32,517	-12,374	61.4%
18,993	17,807	-1,186	-6.2%
-5,900	-6,299	-399	6.8%
0	0	0	
13,094	11,508	-1,585	-12.1%
0	0	0	
244	2,393	2,149	880.9%
-413	-643	-230	55.6%
-169	1,750	1,920	<-1.000%
0	0	0	
12,924	13,258	334	2.6%
-3,710	-3,629	82	-2.2%
-3,330	-2,094	1,237	-37.1%
-380	-1,535	-1,155	303.5%
9,214	9,630	416	4.5%
43	43	0	0.0%
9,171	9,587	416	4.5%
0.90 €	0.95 €	0	5.6%

YTD Jun.2021	YTD Jun.2022	Deviation (YoY)	
215,321	269,830	54,508	25.3%
-3,765	28,611	32,376	-860.0%
6,488	9,806	3,318	51.1%
-73,765	-147,563	-73,799	100.0%
-68,247	-70,286	-2,040	3.0%
-40,318	-55,520	-15,202	37.7%
35,715	34,876	-839	-2.3%
-11,671	-12,604	-933	8.0%
0	0	0	
24,045	22,273	-1,772	-7.4%
0	0	0	
756	3,575	2,818	372.5%
-838	-1,246	-408	48.7%
-82	2,329	2,410	<-1.000%
0	0	0	
23,963	24,601	639	2.7%
-6,820	-7,231	-412	6.0%
-6,067	-4,614	1,453	-23.9%
-753	-2,617	-1,864	247.6%
17,143	17,370	227	1.3%
85	85	0	0.0%
17,058	17,285	227	1.3%
1.68 €	1.71 €	0	1.8%

CASHFLOW STATEMENT

Alzchem Group



CASHFLOW (IN M€)

Consolidated earnings before taxes
Depreciation on fixed and intangible assets
Decrease in pension provisions
Loss (+) / Profit (-) from the sale of non-current assets
Other non-cash income (-) and expenses (+)
Financial result
Interests & Taxes
Increase (+) / Decrease (-) Net Working Capital
Cashflow from ongoing operations (Net cash flow)
Cash outflows for investments in fixed assets
Cash inflows from the sale of fixed assets
Cash inflow from the acquisition / Reverse acquisition
Cashflow from investing activity
Free cashflow
Deposits (+) / Repayment (-) bank loans long-term
Repayment of bank loans long-term
Deposits (+) / Repayment (-) from short-term financing lines
Dividend payments
Payment of reduction in leasing liabilities
Payments for the acquisition of own shares (incl. transaction costs)
Payments to non-controlling interests
Cashflow from financing activity
Net increase / decrease in cash and cash equivalents

Q2 2021	Q2 2022
12,924	13,258
5,900	6,299
-329	-364
-3	-48
-1,428	306
169	-1,750
-2,212	-2,044
2,589	-27,244
17,610	-11,588
-6,420	-7,720
3	48
-6,417	-7,672
11,193	-19,260
-2,824	-2,514
	34,044
-7,821	-10,136
-466	-478
-507	
-11,617	20,917
-423	1,657

1 - 6 2021	1 - 6 2022
23,963	24,601
11,671	12,604
-749	-878
-5	-58
2,552	1,835
82	-2,329
-3,994	-3,789
-7,819	-49,156
25,701	-17,169
-16,414	-15,082
11	61
-16,403	-15,021
9,298	-32,190
-5,807	-5,462
	50,662
-7,821	-10,136
-922	-941
-1,010	
-171	-171
-15,731	33,953
-6,433	1,763

SEGMENT OVERVIEW BY QUARTER

Alzchem Group



SALES

	2020				2021				2022				YTD Q2 2022			
SALES	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Deviation PY (Q2) T€ %	PY T€	Actual T€	
Basics & Intermediates	36,012	38,266	32,320	39,837	41,070	45,178	42,465	47,561	57,441	57,927			12,749 22%	86,248	115,368	
Specialty Chemicals	52,199	57,854	42,995	54,383	56,775	59,330	47,116	57,279	65,279	76,214			16,885 22%	116,105	141,493	
Other and Holding	6,529	6,391	6,058	6,414	6,477	6,492	6,339	6,212	6,675	6,294			-198 -3%	12,969	12,969	
Group Consolidation																
Alzchem Group	94,740	102,511	81,373	100,634	104,321	111,000	95,920	111,052	129,395	140,435			29,435 21%	215,321	269,830	

EBITDA

	2020				2021				2022						YTD Q2 2022	
EBITDA	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Deviation PY (Q2) T€ %		PY T€	Actual T€
Basics & Intermediates	1,903	2,485	2,006	2,587	2,791	3,826	3,118	1,250	2,841	853			-2,973	-348%	6,617	3,695
Specialty Chemicals	10,158	14,457	9,418	10,092	13,947	14,801	10,096	11,820	14,267	16,322			1,521	9%	28,748	30,588
Other and Holding	317	81	361	230	435	-43	512	502	-139	830			873	105%	392	691
Group Consolidation	-63	-201	202	-227	-451	409	112	-1,079	103	-200			-610	304%	-41	-98
Alzchem Group	12,315	16,822	11,986	12,683	16,722	18,993	13,838	12,493	17,072	17,805			-1,189	-7%	35,715	34,876

EXECUTIVE TEAM

Alzchem Group AG



ANDREAS NIEDERMAIER

CEO

WITH ALZCHEM SINCE 1999

AREAS OF RESPONSIBILITY

Company Strategy, Finance & Controlling, Investor Relations & Communication, IT, Risk Management, HR, Supply Chain Management, Legal/Patents & Trademarks

KLAUS ENGLMAIER

COO

WITH ALZCHEM SINCE 1988

AREAS OF RESPONSIBILITY

Production, Engineering, Environment/Safety/Health/Quality, Technology

DR. GEORG WEICHSELBAUMER

CSO

WITH ALZCHEM SINCE 2012


AREAS OF RESPONSIBILITY

Marketing, Sales, Innovation Management & Process Development, R&D, Product Safety and Approval




ALZCHEM GROUP LOCATIONS

Production sites and sales companies



“VERBUND” – FULLY INTEGRATED BUSINESS MODEL

Benefits of the “Verbund” system approach



BENEFITS OF “VERBUND”

- Full control of product quality and specifications
- Lower costs
- Higher financial predictability
- Certainty of supply
- Well positioned to address niche markets
- Economies of scale
- Low carbon footprint

MEGATRENDS AS GROWTH DRIVERS



POPULATION
GROWTH



LONGER LIFE
EXPECTANCY



CLIMATE
CHANGE



SUSTAINABILITY

OUR PRODUCTS AND MARKETS

Successful with proven and new products in various industries







MAIN PRODUCTS		DESCRIPTION	END-MARKETS
SPECIALTY CHEMICALS	CREAMINO®	A feed additive for broilers and pigs	Feed additive
	Creapure®	Premium brand for creatine monohydrate as a food supplement in sports nutrition	Food supplements
	LIVADUR	Dietary supplement with pure creatine	Food supplements
	Dormex®	Plant growth regulator used in fruit production	Agriculture
	BREATHRU'S 301	Additive for plant protection formulations	Agriculture
	Sitofex®	Plant growth regulator used in fruit production	Agriculture
	Alzogur®	Biocide for the prevention of diseases in animal production	Agriculture
	Silzot HQ	Silicon nitride powder for ceramic applications	Ceramics
	Bioselect®	Highly purified form of guanidine salts	Pharmaceuticals / API
	Cyanamide	An organic compound widely used in agriculture and pharmaceuticals	Agriculture and pharmaceuticals
	DYHARD®	Hardeners and accelerators in powder, paste and liquid form	Hardener & Accelerator Systems for Composite Materials
	Thiourea	Various applications incl. flotation agents and pharmaceutical raw materials	Mining and pharmaceuticals
	Nitroguanidine	Intermediates for agrochemical products	Various

OUR PRODUCTS AND MARKETS

Successful with proven and new products in various industries



	MAIN PRODUCTS	DESCRIPTION	END-MARKETS
BASICS & INTERMEDIATES		Calcium carbide-based mixtures for hot metal desulphurization	Steel industry
	Guanidine Salts	Fuel for airbags, key production of the intermediate product	Automotive
	Dicyandiamide	Versatile intermediate in various markets including the pharmaceutical industry	Pharmaceutical Agriculture
		Business fields in color, agro and pharmaceutical applications	Pigments Pharmaceutical
		Reduction of methane emissions during storage of manure	Agriculture
		Special calcium cyanamide multi-effect fertilizer	Agriculture
OTHER & HOLDING	Operation of the Trostberg Chemical Park (companies located at the site: Alzchem, BASF, MBCC Group, Firmenich, Aramark, VIACTIV)		
	Site services		
	Other activities not included in the "Specialty Chemicals" or "Basics & Intermediates" segments		


KEY SHARE DATA

Share Details as of July 22, 2022



SHARES OUTSTANDING	10,176,335 including 40,581 shares held by Alzchem Group AG
LAST CLOSING PRICE	EUR 19.15
MARKET CAPITALIZATION	EUR 194.9 m
TICKER	ACT
WKN	A2YNT3
ISIN	DE000A2YNT30
LISTING	Frankfurt Stock Exchange – Prime Standard
DESIGNATED SPONSOR	Baader Bank AG Oddo Seydler Bank AG

SHAREHOLDER STRUCTURE



As of March 2022. The information on the shareholders is based on the figures reported to us by them. Data regarding the free float are provided in accordance with section 2.3 of the “Guide to the DAX Equity Indices, i.e. considering the number of 40,581 own shares currently held by the company.”